MedNet to Unveil Multiple iMedNet EDC Delivery Options at the 2014 DIA Annual Meeting - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
MedNet to Unveil Multiple iMedNet EDC Delivery Options at the 2014 DIA Annual Meeting

Source: Company News Release

MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, will be showcasing iMedNet EDC, its flagship eClinical solution, at the 2014 Drug Information Association (DIA) Annual Meeting, June 16-18 in San Diego, California. iMedNet EDC provides a flexible, intuitive and affordable eClinical platform that effectively supports research initiatives of any size, phase or duration, in any therapeutic area, anywhere in the world.

MedNet is pleased to offer three iMedNet EDC delivery programs, each designed to support the unique needs and requirements of our customers:

  • iMedNet iBuild Program – Developed for pharma, biotech, IVD and medical device companies wishing to efficiently build their own studies in-house. Includes comprehensive iMedNet Designer training and support services to ensure the success of each research initiative.
  • iMedNet Partner Program – Created specifically for CROs and healthcare consultants looking for a fast, easy-to-use and cost-effective do-it-yourself eClinical solution. Includes complete sales and marketing support, iMedNet Advisory Forum membership and special pricing discounts.
  • iMedNet Access Program – Ideal for any organization wanting to outsource their iMedNet study configurations for any reason. MedNet’s Professional Technology Services Team provides turnkey setup and deployment services, from system build and testing to end-user support.
DIA attendees are encouraged to stop by MedNet’s booth #924 in the exhibits area for more information and to see iMedNet EDC in action. You may also contact MedNet at any time to schedule a free, no-obligation demonstration.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here